Medical Therapies: Study using lead compounds to treat vascular inflammation in rabbits yields promising results

By E. Janene Geiss

Philadelphia, March 28 - Medical Therapies Ltd. announced Tuesday that in a pilot study using rabbits with acute vascular inflammation, two of the company's lead compounds - Copper-Indomethacin and Copper-Acemetacin - exhibited significantly positive results.

The study was conducted at the Heart Research Institute in Sydney, Australia, and was designed to examine the anti-inflammatory effects of a single, oral dose of the company's patent-protected compounds Copper-Indomethacin and Copper-Acemetacin, according to a company news release.

The activity of these drugs was measured against the gold standard, apoA1, the chief protein component of HDL, the body's good cholesterol. ApoA1 nearly completely inhibits inflammation and serves as a control, or gold standard in this model.

In the study, the company's compounds were found to be at least as effective as apoA1, officials said. The compounds exhibited profound inhibition of acute arterial inflammation, officials said.

Medical Therapies said it will now conduct expanded trials and believes that if the pilot study results are mirrored in new trials, there is a significant potential for these drugs as human therapeutics in the treatment of the inflammation associated with heart attacks, stroke and other acute inflammatory states, like post-surgery trauma.

The study was designed only to provide data and only 12 animals were tested in groups of two for each test compound. No statistical significance can be attributed to this data.

Copper-Indomethacin and Copper-Acemetacin are non-steroidal anti-inflammatory drugs (NSAIDs).

Medical Therapies is a Sydney, Australia, product-focused pharmaceutical company developing novel therapeutics for treatment of inflammatory diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.